Foghorn Therapeutics Inc. at Cowen Health Care Conference Transcript
Good afternoon, and welcome once again to TD Cowen's 43rd Annual Healthcare Conference. I'm Eva Privitera, one of the biotech associates here at Cowen. And it's my pleasure to moderate a panel discussion on leukemia with my colleagues Yaron Werber, [Gina Han], Nicholas Lorusso, and [Daniel] Scott.
We are excited to have with us today five executives from key companies in this space. We have Adrian Gottschalk, CEO of Foghorn Therapeutics; Troy Wilson, President & CEO of Kura Oncology; Harout Semerjian, CEO of GlycoMimetics; Anjali Ganguli, Chief Business Officer at Syndax; and finally, Senthil Sundaram, CEO of Terns. We'll start with a few thematic questions for the first 20 minutes or so, and then turn to company-specific questions and go round-robin style.
So to kick us off, we can start with a discussion about running trials in the relapsed and refractory setting. There are still major unmet medical needs in the treatment of relapsed or refractory AML, but also many therapies under development. How do these factors impact your ability to find
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
